Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation. [electronic resource]
- Cancer letters 07 2016
- 149-57 p. digital
Publication Type: Journal Article
1872-7980
10.1016/j.canlet.2016.04.040 doi
Angiogenesis Inhibitors--pharmacology Animals Apoptosis--drug effects Cell Line, Tumor Cell Proliferation--drug effects Deoxyglucose--pharmacology Dose-Response Relationship, Drug Drug Resistance, Neoplasm--drug effects G2 Phase Cell Cycle Checkpoints--drug effects Genetic Predisposition to Disease Glycolysis--drug effects Humans Leukemia, Myeloid, Acute--drug therapy Mice Mitochondria--drug effects Mutation Niacinamide--analogs & derivatives Phenotype Phenylurea Compounds--pharmacology Protein Kinase Inhibitors--pharmacology Pyruvates--pharmacology Signal Transduction--drug effects Sorafenib Tandem Repeat Sequences Time Factors fms-Like Tyrosine Kinase 3--antagonists & inhibitors